title: Multiple cutaneous ecchymoses associated with the administration of bevacizumab.
abstract: Nowadays, the introduction of combinational therapies with biological agents against advanced or resistant to chemotherapy tumors or for the treatment of cancer patients with organ failures becomes more and more attractive. The authors describe the case of a 60-year-old female patient with a multi-refractory to conventional cytotoxic therapy laryngeal cancer that was treated with cetuximab and bevacizumab combination therapy. Bevacizumab administration was associated with appearance of multiple cutaneous ecchymoses. This is a first-time reported adverse effect. Due to the recent launch of these agents and the limited experience of their use in clinical practice, their adverse effects and pharmacological toxicities are not well established and call for their detailed registration and reporting.
authors.affiliation: Department of Medical Oncology - A, Metaxa Cancer Hospital, Piraeus Greece. drtrafalis@aim.com
authors.forename: D T
authors.initials: DT
authors.lastname: Trafalis
authors.forename: A A
authors.initials: AA
authors.lastname: Grivas
authors.forename: A E
authors.initials: AE
authors.lastname: Athanassiou
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects*; D000068258:Bevacizumab; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy; D004438:Ecchymosis / Q000139:chemically induced*; D005260:Female; D006801:Humans; D007822:Laryngeal Neoplasms / Q000188:drug therapy; D008875:Middle Aged; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab